The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

June 30, 2017

Conditions
UrolithiasisRenal Stones
Interventions
DRUG

Oral alkalinization (Potassium citrate, Allopurinol)

"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."

BEHAVIORAL

Life style modification

"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."

DIETARY_SUPPLEMENT

Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)

Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.

Trial Locations (1)

35516

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT02373384 - The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation | Biotech Hunter | Biotech Hunter